The Zhitong Finance App learned that Columbite Biotech (06990) rose by more than 6% and rose 6.04% at press time to HK$163.3, with a turnover of HK$2002 million.
In terms of performance, the company released its first annual report since listing on March 25. In 2023, the company achieved operating income of 1,540 billion yuan, a year-on-year increase of 91.6%; loss during the year was 574 million yuan, a year-on-year decrease of 6.8%; the adjusted loss amount for the year was 451 million yuan, a year-on-year decrease of 24.4%. According to reports, there are currently 7 products in the process of cooperation between Colombotech and MSD. Based on the above cooperation, in 2023, Colombotech received a total of 1,421 billion yuan in down payments and milestone payments from MSD, accounting for 92.27% of the company's revenue during the year.
According to Guolian Securities, overseas, MSD has launched seven global phase III clinical trials, which cover almost the vast majority of NSCLC patients with lung cancer indications from early stage to terminal. In addition, it also targets gastric cancer, endometrial cancer, and HR+/HER2 (low/-) breast cancer endpoints; domestically, Colombotech's cancer layout has advanced clinical progress and has been recognized by regulators. In addition, Colombotech SKB264 is currently undergoing phase II and phase III clinical trials of single drugs/combinations for multiple cancer types around the world, and is expected to become a major ADC product with significant benefits for pan-cancer types.